Trifluoromethyldeschloroketamine

Summary

Trifluoromethyldeschloroketamine, known as TFMDCK, is a member of the arylcyclohexylamine designer drug category. It is believed to share specific properties with ketamine, a dissociative anesthetic renowned for its hallucinogenic and sedative effects. TFMDCK has been available for purchase on the internet since approximately 2016, although authentic samples seem to be scarce. Additionally, the o-trifluoromethyl counterpart of hydroxynorketamine has been explored as a potential antidepressant in scientific research.

Identifiers
IUPAC name
CAS Number1782149-73-8 
PubChem CID117067835
UNIIGW3LZ66WZ6
Chemical and physical data
FormulaC14H16F3NO
Molar mass271.283 g·mol−1

FAQ

1. What is Trifluoromethyldeschloroketamine (TFMDCK)?

  • Trifluoromethyldeschloroketamine, often referred to as TFMDCK, is a designer drug that falls within the arylcyclohexylamine family. It is believed to possess properties similar to ketamine, a well-known dissociative anesthetic with hallucinogenic and sedative effects.

2. How is TFMDCK typically used?

  • TFMDCK is commonly used recreationally. It can be ingested orally, inhaled, or insufflated (snorted). The method of use may vary among individuals.

3. What are the effects of TFMDCK?

  • The effects of TFMDCK are believed to include altered perception, dissociation, and a sense of detachment from reality, akin to ketamine.

4. Is TFMDCK legal?

  • The legal status of TFMDCK can differ by country and region. Users should be aware of the laws in their specific area regarding the possession and use of this substance.

5. Is TFMDCK safe to use?

  • The safety of using TFMDCK is a matter of concern, as its long-term effects and potential risks are not well-documented. Like many designer drugs, there can be health risks associated with use, including unknown purity and possible adverse reactions.

6. What are the risks and side effects of using TFMDCK?

  • Common side effects may include nausea, disorientation, hallucinations, and impaired motor skills. Overdosing can lead to more severe symptoms, such as anxiety, confusion, and potentially life-threatening conditions.

7. Can TFMDCK be addictive?

  • There is a potential for psychological dependence with repeated use, but it is not considered highly physically addictive like some other substances.

8. How can I reduce the risks associated with TFMDCK use?

  • If you choose to use TFMDCK, it’s essential to start with a low dose, be in a safe environment, and have someone you trust present. Avoid mixing it with other substances and be aware of its potential adverse effects.

9. Is there a safe or recommended dosage for TFMDCK?

  • The dosage can vary based on an individual’s tolerance and experience. It’s crucial to begin with a low dose and monitor how your body reacts before considering more.

10. Where can I find help or support for TFMDCK-related issues?

  • If you or someone you know is struggling with substance use or addiction, it’s essential to seek professional help. Reach out to addiction treatment centers or healthcare providers for guidance and support.

11. Is there any research indicating that TFMDCK has potential medicinal uses?

  • While TFMDCK is primarily associated with recreational use, its o-trifluoromethyl counterpart has been studied in scientific research as a potential antidepressant. However, this research is ongoing and not widely established.

References

  1. Wallach J and Brandt SD explored the realm of “1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances” in 2018. Their research was featured in the Handbook of Experimental Pharmacology, Volume 252, spanning pages 305 to 352. The publication can be referenced with DOI: 10.1007/164_2018_148, ISBN: 978-3-030-10560-0, and PMID: 30196446.
  2. A Chinese patent, labeled as CN 110540510A, outlines a method for the preparation of long-acting compounds. This patent was granted on June 18, 2019, detailing innovative techniques in compound synthesis.

Leave a Comment

Your email address will not be published. Required fields are marked *